Comparative Pharmacology
Head-to-head clinical analysis: MOTPOLY XR versus VASOCON A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOTPOLY XR versus VASOCON A.
MOTPOLY XR vs VASOCON-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MOTPOLY XR is a combination of an opioid agonist (morphine) and an opioid antagonist (naltrexone). The extended-release formulation allows for sequential release: an initial morphine dose followed by naltrexone, which mitigates opioid-induced adverse effects by antagonizing mu-opioid receptors in the gastrointestinal tract without affecting central analgesia.
Antazoline is an H1-receptor antagonist that blocks histamine-induced vasodilation and increased capillary permeability. Naphazoline is a direct-acting alpha-adrenergic agonist that constricts conjunctival blood vessels, reducing redness and swelling.
Adults: 10 mg orally once daily, with or without food.
Adults: 1-2 drops in each nostril every 8-12 hours, not to exceed 2 doses per day. Do not use for more than 3 consecutive days.
None Documented
None Documented
Terminal half-life 12–15 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 6-8 hours; extends to 12-18 hours in hepatic impairment.
Renal: ~60% unchanged; biliary/fecal: ~25% as metabolites; <5% unchanged in feces.
Renal excretion of unchanged drug: 60-80%; biliary/fecal: 20-40% as metabolites.
Category C
Category C
Decongestant/Antihistamine Combination
Ophthalmic Decongestant/Antihistamine Combination